Welcome, Guest. Please login or register.
January 17, 2019, 10:12:18 pm

Login with username, password and session length


Members
  • Total Members: 6009
  • Latest: joeycav
Stats
  • Total Posts: 53423
  • Total Topics: 4444
  • Online Today: 69
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 36
Total: 36

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Reconfigured Version of NASH Drug FGF21 Improves Liver Health  (Read 1994 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 549
    • Hep Mag
A retooled version of the non-alcoholic steatohepatitis (NASH) drug FGF21, known as BMS-986036, showed promise in a recent Phase II trial, MedPage Today reports.

The Phase II trial included 74 people with NASH and mild to advanced fibrosis of the liver who received 16 weeks of one of three subcutaneous (injected under the skin) doses: a 10 milligram dose of BMS-986036 given every day, a 20 mg dose given every week, or a placebo given every day.

Findings were presented at the 52nd International Liver Congress in Amsterdam.

Read more...
https://www.hepmag.com/article/reconfigured-version-nash-drug-fgf21-improves-liver-health

 


© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.